Find Clinical Trials by University in Australia

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Australia

Top of Directory » All Categories » by University » Australia



  • CoreValve® System Australia/New Zealand Clinical Study

    Condition:   Aortic Valve Stenosis
    Intervention:   Device: Medtronic CoreValve® System
    Sponsors:   Medtronic Heart Valves;   Medtronic Vascular;   Medtronic Australasia
    Recruiting - verified November 2009
  • A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

    Condition:   Acute Ischemic Stroke
    Interventions:   Biological: Plasmin (Human);   Biological: Plasmin (Human);   Biological: Plasmin (Human)
    Sponsor:   Talecris Biotherapeutics
    Recruiting - verified November 2009
  • Merkel Positron Emission Tomography (PET) Protocol

    Condition:   Stage I or II Merkel Cell Cancer of the Skin
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiotherapy
    Sponsor:   Trans-Tasman Radiation Oncology Group (TROG)
    Not yet recruiting - verified November 2009
  • Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation

    Conditions:   QTc Evaluation;   Electrocardiography
    Interventions:   Drug: Avelox (Moxifloxacin, BAY12-8039);   Drug: Placebo
    Sponsor:   Bayer
    Not yet recruiting - verified November 2009
  • Nexus Compliance Study

    Condition:   Obstructive Sleep Apnea
    Interventions:   Device: Nexus CPAP;   Device: CPAP
    Sponsor:   ResMed
    Not yet recruiting - verified November 2009
  • Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion (PLIF) With Interbody Fusion

    Condition:   Degenerative Disc Disease
    Interventions:   Procedure: Actifuse ABX;   Procedure: INFUSE, plus master granules (MGG)
    Sponsor:   Apatech, Inc.
    Recruiting - verified November 2009
  • A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Lymphocytic Leukemia, Chronic
    Interventions:   Drug: RO5072759;   Drug: rituximab;   Drug: chlorambucil
    Sponsors:   Hoffmann-La Roche;   Genentech
    Not yet recruiting - verified November 2009
  • Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: NN5401;   Drug: biphasic insulin aspart 30
    Sponsor:   Novo Nordisk
    Recruiting - verified November 2009
  • Patient Activated Controlled Expansion (PACE) Trial

    Conditions:   Breast Reconstruction;   Mastectomy
    Intervention:   Device: Patient Activated Controlled Expansion Device
    Sponsor:   AirXpanders, Inc.
    Recruiting - verified November 2009
  • A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Pulmonary Disease, Chronic Obstructive
    Interventions:   Drug: GW642444 Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

    Condition:   Prostate Cancer
    Interventions:   Drug: Zoledronic acid;   Drug: Placebo
    Sponsor:   Austin Health
    Not yet recruiting - verified November 2009
  • Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

    Condition:   Retinal Vein Occlusion
    Interventions:   Drug: VEGF Trap-Eye (BAY86-5321);   Other: Sham treatment
    Sponsors:   Bayer;   Regeneron Pharmaceuticals
    Recruiting - verified November 2009
  • A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Glycopyrronium bromide;   Drug: Placebo
    Sponsor:   Novartis
    Recruiting - verified November 2009
  • Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation

    Condition:   Obesity
    Interventions:   Drug: ephedrine hydrochloride;   Drug: ephedrine hydrochloride
    Sponsor:   Bayside Health
    Not yet recruiting - verified November 2009
  • A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

    Condition:   Meningococcal Disease
    Intervention:   Biological: MenACWY conjugate vaccine plus routine infant vaccines
    Sponsors:   Novartis;   Novartis Vaccines
    Not yet recruiting - verified October 2009
  • Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects

    Condition:   Asthma
    Intervention:   Drug: fluticasone furoate
    Sponsor:   GlaxoSmithKline
    Recruiting - verified October 2009
  • Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections

    Condition:   Gram-Negative Bacterial Infection
    Interventions:   Drug: AN3365;   Drug: Placebo
    Sponsor:   Anacor Pharmaceuticals, Inc.
    Recruiting - verified November 2009
  • A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers

    Conditions:   Cystic Fibrosis;   Mucociliary Clearance;   Airway Hydration
    Interventions:   Drug: GS-9411;   Drug: Placebo
    Sponsor:   Gilead Sciences
    Recruiting - verified November 2009
  • Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers

    Condition:   Cancer
    Interventions:   Drug: Placebo;   Drug: GSK2256098
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

    Condition:   Arrhythmia Prophylaxis
    Interventions:   Drug: Celivarone (SSR149744);   Drug: amiodarone;   Drug: placebo
    Sponsor:   Sanofi-Aventis
    Recruiting - verified November 2009
  • Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer

    Condition:   Rectal Cancer
    Interventions:   Radiation: External Beam Radiotherapy;   Drug: Oxaliplatin;   Drug: Fluorouracil;   Drug: Leucovorin;   Procedure: Surgical Resection
    Sponsor:   Trans-Tasman Radiation Oncology Group (TROG)
    Not yet recruiting - verified November 2009
  • Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC)

    Condition:   Stage 1 Non Small Cell Lung Cancer
    Interventions:   Radiation: Hypofractionated radiotherapy (HypoRT);   Radiation: Conventionally Fractionated Radiotherapy (ConRT)
    Sponsor:   Trans-Tasman Radiation Oncology Group (TROG)
    Not yet recruiting - verified November 2009
  • A Study of Tocilizumab in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

    Condition:   Juvenile Idiopathic Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: tocilizumab;   Drug: placebo;   Drug: NSAIDs, corticosteroids, methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

    Conditions:   Hepatitis C;   Thrombocytopaenia
    Intervention:   Drug: Eltrombopag
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • A Study of Patients With Major Depressive Disorder and Residual Apathy

    Condition:   Major Depressive Disorder
    Interventions:   Drug: Duloxetine;   Drug: Escitalopram
    Sponsors:   Eli Lilly and Company;   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified November 2009
  • A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

    Condition:   Neoplasms
    Interventions:   Drug: R1507;   Drug: RAD001
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

    Condition:   Chronic Hepatitis C Genotype-1 Relapse
    Interventions:   Drug: NIM811;   Drug: Placebo BID + SOC
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009
  • Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

    Condition:   Influenza
    Interventions:   Drug: Oseltamivir Phosphate;   Drug: ADS-8902
    Sponsor:   Adamas Pharmaceuticals, Inc.
    Recruiting - verified September 2009
  • The Severe Soft Tissue Bleeding Study

    Condition:   Soft Tissue Bleeding
    Interventions:   Biological: Fibrin Pad;   Procedure: Standard of Care
    Sponsor:   Ethicon, Inc.
    Recruiting - verified November 2009
  • 24-Week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50

    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Sitagliptin
    Sponsor:   Sanofi-Aventis
    Recruiting - verified November 2009
  • TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

    Condition:   Hepatitis C
    Interventions:   Drug: TMC435 placebo /Peg IFNa2A/Ribavirin;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin
    Sponsor:   Tibotec Pharmaceuticals, Ireland
    Recruiting - verified November 2009
  • Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

    Conditions:   Chronic Allograft Nephropathy;   Chronic Kidney Disease;   Chronic Renal Failure;   Disordered Mineral Metabolism;   End Stage Renal Disease;   Hyperparathyroidism;   Hypophosphatemia;   Kidney Disease;   Kidney Transplantation;   Post Renal Transplantation
    Interventions:   Drug: Placebo;   Drug: Cinacalcet
    Sponsor:   Amgen
    Not yet recruiting - verified November 2009
  • Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

    Condition:   Castration-Resistant Prostate Cancer
    Interventions:   Drug: MDV3100;   Drug: Placebo
    Sponsor:   Medivation, Inc.
    Recruiting - verified November 2009
  • A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

    Condition:   Benign Prostatic Hyperplasia
    Interventions:   Drug: Tadalafil;   Drug: Placebo tablet;   Drug: Tamsulosin;   Drug: Placebo capsule
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009
  • An Exploratory Study of a Nasal Dilator Strip

    Condition:   Sleep Disordered Breathing
    Intervention:   Device: Prototype nasal dilator
    Sponsor:   GlaxoSmithKline
    Recruiting - verified October 2009
  • Study in Neuropathic Pain Patients With Peripheral Nerve Injury

    Condition:   Neuropathic Pain
    Interventions:   Drug: GW856553;   Drug: PLACEBO
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

    Condition:   Hepatitis C, Chronic
    Interventions:   Drug: RO5190591;   Drug: RO5190591;   Drug: RO5190591;   Drug: RO5190591;   Drug: Placebo;   Drug: Placebo;   Drug: Pegasys;   Drug: Copegus
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Safety Study of NNZ-2566 in Healthy Female Subjects

    Condition:   Brain Injuries, Traumatic
    Interventions:   Drug: NNZ-2566;   Drug: Placebo
    Sponsor:   Neuren Pharmaceuticals Limited
    Not yet recruiting - verified November 2009
  • Study of Bosutinib With Capecitabine in Solid Tumors and Locally Advanced or Metastatic Breast Cancer

    Condition:   Advanced Breast Cancer
    Interventions:   Drug: Bosutinib;   Drug: Capecitabine
    Sponsor:   Wyeth
    Recruiting - verified October 2009
  • Study of Blood Samples From Newborns With Down Syndrome

    Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

    Condition:   Arthritis, Juvenile Idiopathic
    Intervention:   Drug: Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
    Sponsor:   Wyeth
    Recruiting - verified November 2009
  • COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

    Condition:   Myelofibrosis
    Interventions:   Drug: INCB018424;   Drug: Placebo
    Sponsor:   Incyte Corporation
    Recruiting - verified November 2009
  • Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: AZD1152;   Drug: LDAC;   Drug: AZD1152 + LDAC
    Sponsor:   AstraZeneca
    Recruiting - verified November 2009
  • A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

    Condition:   Malignant Melanoma
    Intervention:   Drug: RO5185426
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • A Study of Genz-112638 in Patients With Gaucher Disease Who Have Been Stabilized on Cerezyme

    Condition:   Gaucher Disease, Type 1
    Interventions:   Drug: Genz-112638;   Biological: Cerezyme
    Sponsor:   Genzyme
    Recruiting - verified July 2009
  • The Elite Athlete Mental Health Strategy Trial

    Condition:   Mental Health Help-Seeking
    Interventions:   Other: Control;   Other: Destigmatisation and Mental Health Literacy;   Other: Help-seeking list;   Other: Feedback
    Sponsors:   Australian National University;   Australian Institute of Sport
    Recruiting - verified November 2009
  • Clazosentan in Aneurysmal Subarachnoid Hemorrhage

    Condition:   Aneurysmal Subarachnoid Hemorrhage
    Interventions:   Drug: Clazosentan;   Drug: Clazosentan;   Drug: Placebo
    Sponsor:   Actelion
    Recruiting - verified November 2009
    • Menu
    Find Paid Clinical Trials